The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•11 May 2026•

1 min read

DaVita Stock Surges 23% on Q1 Earnings Beat and Raised 2026 Guidance

Key Facts

1DaVita reported adjusted earnings per share of $2.87, beating analyst estimates by 19.1%.

2Company revenue grew by 5.9% to $3.42 billion, driven by steady demand for dialysis services.

3Cowen & Co raised its price target for DVA to $201 from $144 while maintaining a Hold rating.

DaVita reported strong Q1 financial results, with adjusted earnings per share reaching $2.87, surpassing analyst estimates by 19.1%. Revenue grew by 5.9% to $3.42 billion, driven by steady demand for dialysis services. Following the report, Cowen & Co raised its price target for DVA stock to $201 from $144 while maintaining a Hold rating.

This robust performance comes as the healthcare sector sees mixed results, with DaVita benefiting from expanding operating margins that reached 19.1% and aggressive share buyback programs. Compared to healthcare service peers, the company demonstrated high resilience against operating costs, per market data. Additionally, the company raised its full-year 2026 adjusted EPS guidance to a range of $14.10 to $15.20, reflecting management's confidence in sustained growth.

DVA stock closed at elevated levels following the earnings announcement (close May 12, 2026), with investors now monitoring margin stability in upcoming quarters. Regarding the economic calendar, traders are looking ahead to the U.S. Initial Jobless Claims scheduled for May 7, 2026, which could influence broader market sentiment toward healthcare and growth stocks.